GTBP earnings date and last-quarter result: next report 2026-08-13, last quarter miss, P/E -0.05. Updated 2026-07-23.
GT Biopharma (GTBP) Research Hub
GT Biopharma (GTBP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 5.07 USD (-7.14%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.05, market cap 0.00B. This hub links to the full technical, earnings and options research available for GTBP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.07 USD (-7.14%) |
| 52-week range | 4.91 USD – 13.94 USD |
| Trend regime | Range |
| 14-day RSI | 40.4 (Bearish) |
| Trailing P/E | -0.05 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for GTBP
Covered Call on GTBP: how it works, illustrative setup around the real 5.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GTBP: how it works, illustrative setup around the real 5.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GTBP: how it works, illustrative setup around the real 5.07 USD price, max profit/loss, breakeven and when to use it. Educational.
GTBP technical analysis: range, last 5.07 USD, RSI 40.4, 52w range 4.91 USD–13.94 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GTBP in?
GT Biopharma (GTBP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GTBP in an uptrend or downtrend?
As of 2026-10-26, GTBP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GTBP's trailing P/E ratio?
GTBP's trailing P/E is -0.05, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does GTBP next report earnings?
GTBP is next scheduled to report earnings on 2026-08-13.